The MARLINA-T2D study, which was the first clinical trial to evaluate the effects of linagliptin on renal outcomes in T2DM patients with proteinuria on top of standard therapy, failed to demonstrate a significant reduction in urinary albumin levels (Groop et al., 2017). This evidence concerns the gene ALB and type 2 diabetes mellitus.